Evidence map›Paper›PMID 40926575›Full record

ArticleMedical physics2025

Development and characterization of a prototype selenium-75 high dose rate brachytherapy source.

Jonathan Kalinowski, Oren Tal, Jake Reid, John Munro, Matthew Moran, Andrea Armstrong, Shirin A Enger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jonathan KalinowskiMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
Oren TalLady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada.
Jake ReidMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
John MunroBurnley Technology Inc., Seabrook, New Hampshire, USA.
Matthew MoranNuclear Operations and Facilities, McMaster University, Hamilton, Ontario, Canada.
Andrea ArmstrongDepartment of Chemistry & Chemical Biology, McMaster University, Hamilton, Ontario, Canada.
Shirin A EngerMedical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.

Funding

Canada Research Chairs 252135CIHR 170620Fonds de recherche du Québec - Nature et technologies 343972Institut TransMedTech
6 · The paper itself

Abstract

backgroundPURPOSE: A novel

methodsThe source was modeled and integrated into the Monte Carlo-based treatment planning system RapidBrachyMCTPS, where its TG-43U1 parameters, photon spectrum, and broad beam first half-value layers (HVL

resultsThe SeCure source's TG-43U1 parameters were computed, showing that

conclusionsThe SeCure design possesses the dosimetric, spectral, and physical properties necessary for a feasible high dose rate brachytherapy source. Next, manufacturing of a high-activity SeCure source will be pursued.

Indexed as

BrachytherapyRadiation DosageSeleniumMonte Carlo MethodRadiometryRadiotherapy DosageSeleniumbrachytherapydosimetryMonte Carloselenium‐75

Identifiers

PMID40926575
PMCPMC12421221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.